- Extreme weather destabilizing supply of raw materials and causing workflow delays.
- Tightening regulatory requirements related to climate change increasing operating costs.
- Growing market concern about climate change increasing demand for environmentally friendly products.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Greenhouse gas emissions & sustainability report data
In its 2022 reporting, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. disclosed greenhouse gas emissions of 58.3K tonnes of carbon dioxide equivalent. By scope: Scope 1: 24.4K tonnes of carbon dioxide equivalent; Scope 2: 34.0K tonnes of carbon dioxide equivalent. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
58.3K tonnes of carbon dioxide equivalent
2022
Water Usage
853.4K m3
2022
Waste
685.1 tonnes (Hazardous: 151.3 tonnes, Non-hazardous: 589.0 tonnes)
2022
Energy Use
182.1K kWh in '000s
2022
📊 Emissions by Scope (2022)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 24.4K tonnes of carbon dioxide equivalent |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 34.0K tonnes of carbon dioxide equivalent |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- All factories in Shenzhen obtained Clean Production Certification.
- Greenhouse gas emissions in Scope 1 and Scope 2 were lower than the previous year.
- Implemented energy-saving measures to reduce energy consumption and greenhouse gas emissions.
- Over 90% of laser toner cartridges were recyclable.
🌱 ESG Focus Areas
Environmental ProtectionEmployment and Labor PracticesBusiness PracticesCommunity Investment